Design and Pre-Clinical Evaluation of a Universal HIV-1 Vaccine
暂无分享,去创建一个
Bette Korber | Tao Dong | Lucy Dorrell | Andrew J. McMichael | B. Korber | A. McMichael | T. Hanke | T. Dong | L. Dorrell | Sven Létourneau | Eung-Jun Im | Tumelo Mashishi | Choechoe Brereton | Anne Bridgeman | Hongbing Yang | Tomáš Hanke | Hongbing Yang | E. Im | A. Bridgeman | S. Létourneau | T. Mashishi | Choechoe Brereton
[1] S. Rowland-Jones,et al. Expansion and Diversification of Virus-Specific T Cells following Immunization of Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Individuals with a Recombinant Modified Vaccinia Virus Ankara/HIV-1 Gag Vaccine , 2006, Journal of Virology.
[2] Feng Gao,et al. Diversity Considerations in HIV-1 Vaccine Selection , 2002, Science.
[3] David Heckerman,et al. Control of human immunodeficiency virus replication by cytotoxic T lymphocytes targeting subdominant epitopes , 2006, Nature Immunology.
[4] J. Haas,et al. Increased Immune Response Elicited by DNA Vaccination with a Synthetic gp120 Sequence with Optimized Codon Usage , 1998, Journal of Virology.
[5] A. McMichael,et al. HIV T cell vaccines, the importance of clades. , 2002, Vaccine.
[6] H. Teppler,et al. The effect of epitope variation on the profile of cytotoxic T lymphocyte responses to the HIV envelope glycoprotein. , 1998, International immunology.
[7] B. Walker,et al. AIDS: Escape from the immune system , 2000, Nature.
[8] Lucy Dorrell,et al. Cytotoxic T lymphocytes recognize structurally diverse, clade‐specific and cross‐reactive peptides in human immunodeficiency virus type‐1 gag through HLA‐B53 , 2001, European journal of immunology.
[9] A. McMichael,et al. Combined single‐clade candidate HIV‐1 vaccines induce T cell responses limited by multiple forms of in vivo immune interference , 2007, European journal of immunology.
[10] F Gotch,et al. Recognition of influenza A matrix protein by HLA-A2-restricted cytotoxic T lymphocytes. Use of analogues to orientate the matrix peptide in the HLA-A2 binding site , 1988, The Journal of experimental medicine.
[11] B. Walker,et al. Recognition of a highly conserved region of human immunodeficiency virus type 1 gp120 by an HLA-Cw4-restricted cytotoxic T-lymphocyte clone , 1993, Journal of virology.
[12] Philip J. R. Goulder,et al. HIV and SIV CTL escape: implications for vaccine design , 2004, Nature Reviews Immunology.
[13] A. Sette,et al. Natural variants of cytotoxic epitopes are T-cell receptor antagonists for antiviral cytotoxic T cells , 1994, Nature.
[14] J. Mascola,et al. Multiclade Human Immunodeficiency Virus Type 1 Envelope Immunogens Elicit Broad Cellular and Humoral Immunity in Rhesus Monkeys , 2005, Journal of Virology.
[15] J. Herndon,et al. Studies on the cross-clade and cross-species conservation of HIV-1 Gag-specific CD8 and CD4 T cell responses elicited by a clade B DNA/MVA vaccine in macaques. , 2005, Virology.
[16] A. McMichael,et al. Clinical experience with plasmid DNA- and modified vaccinia virus Ankara-vectored human immunodeficiency virus type 1 clade A vaccine focusing on T-cell induction. , 2007, The Journal of general virology.
[17] J. Frelinger,et al. Cross-clade human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte responses in HIV-infected Zambians , 1997, Journal of virology.
[18] S. Rowland-Jones,et al. Cytotoxic T cell responses to multiple conserved HIV epitopes in HIV-resistant prostitutes in Nairobi. , 1998, The Journal of clinical investigation.
[19] M. McElrath,et al. Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[20] Maureen F. Maughan,et al. Characterization and selection of HIV-1 subtype C isolates for use in vaccine development. , 2003, AIDS research and human retroviruses.
[21] C. Moore,et al. Evidence of HIV-1 Adaptation to HLA-Restricted Immune Responses at a Population Level , 2002, Science.
[22] L. Corey,et al. HIV vaccines: new frontiers in vaccine development. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[23] Todd M. Allen,et al. Characterization of the peptide binding motif of a rhesus MHC class I molecule (Mamu-A*01) that binds an immunodominant CTL epitope from simian immunodeficiency virus. , 1998, Journal of immunology.
[24] S. Rowland-Jones,et al. Modified vaccinia Ankara expressing HIVA antigen stimulates HIV-1-specific CD8 T cells in ELISpot assays of HIV-1 exposed infants. , 2005, Vaccine.
[25] J. Mascola,et al. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. , 2006, The Journal of infectious diseases.
[26] Alessandro Sette,et al. Development of a DNA Vaccine Designed to Induce Cytotoxic T Lymphocyte Responses to Multiple Conserved Epitopes in HIV-1 1 , 2003, The Journal of Immunology.
[27] B. Walker,et al. Identification of overlapping HLA class I-restricted cytotoxic T cell epitopes in a conserved region of the human immunodeficiency virus type 1 envelope glycoprotein: definition of minimum epitopes and analysis of the effects of sequence variation , 1992, The Journal of experimental medicine.
[28] D. Nickle,et al. Reconstruction and Function of Ancestral Center-of-Tree Human Immunodeficiency Virus Type 1 Proteins , 2007, Journal of Virology.
[29] P. Allen,et al. In vivo antagonism of a T cell response by an endogenously expressed ligand. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[30] T. Hanke,et al. Short communication: preclinical evaluation of candidate HIV type 1 vaccines in inbred strains and an outbred stock of mice. , 2007, AIDS research and human retroviruses.
[31] B. Walker,et al. HIV-1 gag-specific cytotoxic T lymphocytes recognize multiple highly conserved epitopes. Fine specificity of the gag-specific response defined by using unstimulated peripheral blood mononuclear cells and cloned effector cells. , 1991, Journal of immunology.
[32] B. Korber,et al. Evolutionary and immunological implications of contemporary HIV-1 variation. , 2001, British medical bulletin.
[33] D. Wiley,et al. Peptide recognition by two HLA-A2/Tax11-19-specific T cell clones in relationship to their MHC/peptide/TCR crystal structures. , 1999, Journal of immunology.
[34] B. Walker,et al. Recognition of the highly conserved YMDD region in the human immunodeficiency virus type 1 reverse transcriptase by HLA-A2-restricted cytotoxic T lymphocytes from an asymptomatic long-term nonprogressor. , 1996, The Journal of infectious diseases.
[35] John Sidney,et al. Identification and Antigenicity of Broadly Cross-Reactive and Conserved Human Immunodeficiency Virus Type 1-Derived Helper T-Lymphocyte Epitopes , 2001, Journal of Virology.
[36] P. Srivastava,et al. Immunization against a dominant tumor antigen abrogates immunogenicity of the tumor. , 2002, Cancer immunity.
[37] D. Kwiatkowski,et al. Association of malaria parasite population structure, HLA, and immunological antagonism. , 1998, Science.
[38] P. Klenerman,et al. HIV: current opinion in escapology. , 2002, Current opinion in microbiology.
[39] A. McMichael,et al. Engineering RENTA, a DNA prime-MVA boost HIV vaccine tailored for Eastern and Central Africa , 2004, Gene Therapy.
[40] Wayne C Koff,et al. HIV vaccine design and the neutralizing antibody problem , 2004, Nature Immunology.
[41] S. Osmanov,et al. Identification of highly conserved and broadly cross-reactive HIV type 1 cytotoxic T lymphocyte epitopes as candidate immunogens for inclusion in Mycobacterium bovis BCG-vectored HIV vaccines. , 2000, AIDS research and human retroviruses.
[42] Feng Gao,et al. Antigenicity and immunogenicity of HIV-1 consensus subtype B envelope glycoproteins. , 2007, Virology.
[43] E. Rosenberg,et al. Recognition of a Defined Region within p24 Gag by CD8+ T Cells during Primary Human Immunodeficiency Virus Type 1 Infection in Individuals Expressing Protective HLA Class I Alleles , 2007, Journal of Virology.
[44] B. Korber,et al. Consistent Patterns of Change during the Divergence of Human Immunodeficiency Virus Type 1 Envelope from That of the Inoculated Virus in Simian/Human Immunodeficiency Virus-Infected Macaques , 2006, Journal of Virology.
[45] R. Siliciano,et al. Induction of a major histocompatibility complex class I-restricted cytotoxic T-lymphocyte response to a highly conserved region of human immunodeficiency virus type 1 (HIV-1) gp120 in seronegative humans immunized with a candidate HIV-1 vaccine , 1994, Journal of virology.
[46] Daniel C. Douek,et al. T Cell Cross-Reactivity and Conformational Changes during TCR Engagement , 2004, The Journal of experimental medicine.
[47] C. Rouzioux,et al. Cross-clade-specific cytotoxic T lymphocytes in HIV-1-infected children. , 1998, Virology.
[48] D. Heckerman,et al. Founder Effects in the Assessment of HIV Polymorphisms and HLA Allele Associations , 2007, Science.
[49] Bette T. Korber,et al. Antigenicity and Immunogenicity of a Synthetic Human Immunodeficiency Virus Type 1 Group M Consensus Envelope Glycoprotein , 2005, Journal of Virology.
[50] Z. Weng,et al. Ancestral and consensus envelope immunogens for HIV-1 subtype C. , 2006, Virology.
[51] A. McMichael,et al. DNA multi-CTL epitope vaccines for HIV and Plasmodium falciparum: immunogenicity in mice. , 1998, Vaccine.
[52] A. McMichael,et al. Design and construction of an experimental HIV-1 vaccine for a year-2000 clinical trial in Kenya. , 2000, Nature Medicine.
[53] G. Pialoux,et al. [HIV vaccines]. , 2005, Presse medicale.
[54] Hua-Xin Liao,et al. Centralized immunogens as a vaccine strategy to overcome HIV-1 diversity , 2004, Expert review of vaccines.
[55] G. Ogg,et al. Immunogenicities of intravenous and intramuscular administrations of modified vaccinia virus Ankara-based multi-CTL epitope vaccine for human immunodeficiency virus type 1 in mice. , 1998, The Journal of general virology.
[56] R. Randall,et al. Construction of solid matrix-antibody-antigen complexes containing simian immunodeficiency virus p27 using tag-specific monoclonal antibody and tag-linked antigen. , 1992, The Journal of general virology.
[57] B. Walker,et al. Cytotoxic T-lymphocyte cross-reactivity among different human immunodeficiency virus type 1 clades: implications for vaccine development , 1997, Journal of virology.
[58] J. Mascola,et al. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine. , 2006, The Journal of infectious diseases.
[59] James Theiler,et al. Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants , 2007, Nature Medicine.
[60] Feng Gao,et al. Cross-Subtype T-Cell Immune Responses Induced by a Human Immunodeficiency Virus Type 1 Group M Consensus Env Immunogen , 2006, Journal of Virology.
[61] A. Hill,et al. Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous prime-boost immunisation regimes. , 2002, Vaccine.
[62] E. Rosenberg,et al. Substantial Differences in Specificity of HIV-Specific Cytotoxic T Cells in Acute and Chronic HIV Infection , 2001, The Journal of experimental medicine.
[63] A. Hill,et al. Altered peptide ligands narrow the repertoire of cellular immune responses by interfering with T-cell priming , 1999, Nature Medicine.
[64] M. Kozak. An analysis of 5'-noncoding sequences from 699 vertebrate messenger RNAs. , 1987, Nucleic acids research.
[65] Lucy Dorrell,et al. Induction of Multifunctional Human Immunodeficiency Virus Type 1 (HIV-1)-Specific T Cells Capable of Proliferation in Healthy Subjects by Using a Prime-Boost Regimen of DNA- and Modified Vaccinia Virus Ankara-Vectored Vaccines Expressing HIV-1 Gag Coupled to CD8+ T-Cell Epitopes , 2006, Journal of Virology.
[66] Todd M. Allen,et al. Enhanced Detection of Human Immunodeficiency Virus Type 1-Specific T-Cell Responses to Highly Variable Regions by Using Peptides Based on Autologous Virus Sequences , 2003, Journal of Virology.
[67] D. Nickle,et al. Reconstruction and function of Ancestral Center-Of-Tree ( COT ) HIV-I Proteins Running title : COT protein derivation and function , 2007 .
[68] S. L. Silins,et al. T cell receptor repertoire for a viral epitope in humans is diversified by tolerance to a background major histocompatibility complex antigen , 1995, The Journal of experimental medicine.
[69] C. DeLisi,et al. An immunodominant epitope of the human immunodeficiency virus envelope glycoprotein gp160 recognized by class I major histocompatibility complex molecule-restricted murine cytotoxic T lymphocytes. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[70] Sarah Rowland-Jones,et al. Cytotoxic T-cell activity antagonized by naturally occurring HIV-1 Gag variants , 1994, Nature.
[71] H. Rammensee,et al. Protective Immunity Does Not Correlate with the Hierarchy of Virus-specific Cytotoxic T Cell Responses to Naturally Processed Peptides , 1998, The Journal of experimental medicine.
[72] S. Rowland-Jones,et al. Distinct Recognition of Non-Clade B Human Immunodeficiency Virus Type 1 Epitopes by Cytotoxic T Lymphocytes Generated from Donors Infected in Africa , 1999, Journal of Virology.
[73] Hao Shen,et al. In Vivo Modulation of T Cell Responses and Protective Immunity by TCR Antagonism during Infection1 , 2005, The Journal of Immunology.